Conjugated Estrogens Cream + Placebo Cream
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pelvic Organ Prolapse
Conditions
Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Trial Timeline
Dec 1, 2016 → May 17, 2023
NCT ID
NCT02431897About Conjugated Estrogens Cream + Placebo Cream
Conjugated Estrogens Cream + Placebo Cream is a approved stage product being developed by Pfizer for Pelvic Organ Prolapse. The current trial status is completed. This product is registered under clinical trial identifier NCT02431897. Target conditions include Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02431897 | Approved | Completed |
Competing Products
11 competing products in Pelvic Organ Prolapse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 85 |
| BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 22 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 51 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 30 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 74 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |